AlphaMark Advisors’s Takeda Pharmaceutical TAK Stock Holding History

AlphaMark Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-79	Closed	-$1K	–	618
2020 Q1	$1K	Buy	+79	New	+$1.43K	﹤0.01%	545

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

AlphaMark Advisors's TAK Position: Q2 2020 in Review

AlphaMark Advisors sold out of Takeda Pharmaceutical (TAK) in Q2 2020, closing a stake of 79 shares — an estimated $1K sold.

AlphaMark Advisors first reported a position in TAK in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 309 funds tracked by Wall St. Rank hold TAK as of Q2 2020.

AlphaMark Advisors reported no remaining Takeda Pharmaceutical position as of Q2 2020 after selling out during the quarter.
AlphaMark Advisors sold 79 Takeda Pharmaceutical shares in Q2 2020, an estimated $1K.
AlphaMark Advisors first reported a position in Takeda Pharmaceutical in Q1 2020 and held it in 1 quarter.
AlphaMark Advisors's Takeda Pharmaceutical position peaked at $1K in Q1 2020.
309 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2020.

Based on AlphaMark Advisors's 13F filing for Q2 2020, filed 10 Aug 2020.